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Recently, several drugs for non-cardiovascular diseases have ceased marketing because of cardiovascu-
lar risk, highlighting the importance of evaluating the cardiovascular safety of new drugs even if not
intended for cardiovascular diseases. Assessing and ensuring acceptable cardiovascular safety of non-
cardiovascular drugs is difﬁcult; nonetheless, governmental regulatory agencies are likely to change
the requirements for drug safety information. This article explores our recommendations for rethinking
current regulatory policies, emphasizing the need for mandatory post-marketing surveillance registries
and highlighting the exposures necessary to subserve the need for greater assessment of safety issues.
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Introduction
All drugs have multiple pharmacological actions, some ben-
eﬁcial and some detrimental. The perceived relation
between beneﬁt and risk, deﬁned from pre-approval
studies, forms the basis for drug approval and drug use. Pre-
approval requirements must enable (i) delivery of effective
and acceptably safe therapy to the public as quickly as is
reasonable, (ii) information for prescribers sufﬁcient to
assure administration plans that will maximize beneﬁt and
minimize risk, and (iii) fairness to drug manufacturers to
maintain incentives for drug development. The resulting
process yields a body of information that, at drug approval,
is unlikely to deﬁne all clinically important risks associated
with drug use, especially those involving rare events that
are difﬁcult to detect after the relatively modest mandatory
pre-approval drug exposure but may appear when a drug
is in widespread clinical use. Indeed, pharmacological
actions of a single drug can differ among functionally differ-
ent organ systems; beneﬁt for non-cardiovascular targets
may be associated with cardiovascular adversity. However,
cardiovascular testing is not a major focus of evaluation
and development of non-cardiovascular drugs. Conse-
quently, at approval, the relation between non-
cardiovascular beneﬁt and cardiovascular risk may not be
adequately deﬁned.
Deﬁciencies of pre-approval data are exempliﬁed by
issues emerging from the withdrawal of two non-steroidal
anti-inﬂammatory drugs (NSAIDs), both cyclo-oxygenase
(COX)-2 selective.1–4 These actions followed several publi-
cations associating NSAIDs with cardiovascular event rates
higher than observed among non-drug users, and highlight-
ing the effects of COX-2 selective agents, the most recently
approved members of this drug group.5–11 These deﬁciencies
are difﬁcult to remedy within current regulatory algorithms,
which create barriers to detecting relatively uncommon
adverse events before approval. The problem is illustrated
in Table 1, with absolute event rates taken from the
Adenoma Prevention with Celecoxib (APC) trial (n ¼ 2035
patients). A clear relative risk gradient was apparent
between placebo and the two doses of celecoxib. However,
the number of patients employed in this post-approval trial
exceeded the total required patient exposure needed to
meet pre-approval regulatory requirements. Current laws
do not permit regulatory agencies to mandate such post-
approval studies; current regulations limit mandatory pre-
approval exposure to limit unfair development costs in
the absence of a compelling evidentiary basis (see in
what follows). Given the relatively modest absolute risks
observed in APC, an a priori commitment from the manufac-
turer (revocable at any time under current laws) would have
been needed to assure a post-approval trial with power ade-
quate for likely detection of the relative risks actually
observed. Thus, it is fair to question whether we need a
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new conceptual basis for assessment and approval. This
article provides some responsive suggestions, developed at
a meeting of cardiovascular clinical trialists, biostatisti-
cians, FDA and European Medicines Agency (EMEA) regula-
tors, representatives of the National Institutes of Health
(NIH), and pharmaceutical industry scientists in Versailles,
France, in December 2005.
Background
The NSAIDs are not the ﬁrst drugs for non-cardiovascular
targets evidencing unexpected cardiovascular risk after
market release. For example, in 1997, fenﬂuramine and
dexfenﬂuramine were withdrawn when data suggested
they could cause cardiac valvular disease.12–16 The following
year, terfenadine was withdrawn because of association with
fatal cardiac arrhythmias when it was administered with
cytochrome p450 enzyme system inhibitors;17,18 2 years
later, cisapride was withdrawn upon reports of cardiac
arrhythmias and deaths.19
Thus, new approaches are needed to document cardiovas-
cular effects of new pharmacological agents not intended
for cardiovascular targets. However, potential pathophysio-
logical links may not be evident between cardiovascular
events and drugs prescribed for non-cardiac conditions, par-
ticularly when clinical trials for the primary disease targets
are short-term or if the relevant populations already are at
risk for cardiovascular disease because of age, systemic
inﬂammatory diseases, or other conditions. Even in the pre-
approval period, detection of cardiovascular events during
rigorous clinical trials of ‘non-cardiovascular’ drugs gener-
ally relies on spontaneous reporting of adverse events by
investigators not trained in cardiology, who may not recog-
nize subtle cardiovascular complaints. Most importantly, as
noted earlier, pre-approval patient exposure requirements
provide scant statistical power to detect differences in
rates of infrequent events between the new drug and com-
parators, especially if pre-treatment cardiovascular risk is
low. In the absence of organized trials, post-approval detec-
tion depends on spontaneous cardiac event reporting by
practitioners (largely non-cardiologists), a notoriously insen-
sitive and inefﬁcient approach.
Because of these considerations and experiences, the
United States Food and Drug Administration (FDA) is likely
to change its process for evaluating drug safety.20 Optimally,
such change should deﬁne the type and magnitude of cardi-
ovascular risks that must be detected before marketing to
adequately protect public health. If pre-approval studies
can assure that these important adverse events occur at
less than a pre-speciﬁed rate, further information may not
be necessary prior to approval,21 though post-approval
data enhancement may be useful. Concomitantly, the scien-
tiﬁc rigor required to establish the association between a
new drug and cardiovascular risk must be established, i.e.
when must the relevant data come from prospective, ran-
domized clinical trials, when will registries (voluntary
inclusion or mandated consecutive patient series) sufﬁce,
and when will retrospective prescription-based data sets
be adequate.
Classiﬁcation of cardiovascular risk
The drug development process aims to deﬁne the beneﬁts
and risks of an investigational agent for a speciﬁc popu-
lation. Results may be skewed by patient selection criteria
in pre-approval clinical trials, which generally are designed
to eliminate characteristics that might confound interpret-
ation of the primary study outcome, e.g. childhood or
advanced age, pregnancy, or patients with various comor-
bidities (thus optimizing likelihood of observing a drug
effect if it exists). The resulting cohort can differ impor-
tantly from the population that will receive the drug after
approval. In addition, the duration of observation in clinical
trials commonly is shorter than the prolonged exposure in
clinical settings. Regulatory agencies often require trial dur-
ations in part based on the presumption that, since spon-
taneous reports of major problems in long-term use
generally have been rare in the past, mandatory pro-
longation of trials is not needed. However, as earlier,
recent experience belies this presumption.
Prolonging pre-approval trials or increasing sample sizes
to detect rare events during a relatively short interval
have potentially important drawbacks. The costs of trials
can increase dramatically with duration. However, patent
life, the basis upon which drug manufacturers can recoup
their development costs, is relatively short. Increasing the
size of study cohorts may maintain study duration but also
is associated with increasing costs of patient evaluation
and of accelerated recruitment. Consequently, decisions to
prolong and/or enlarge pre-approval trials to detect rela-
tively infrequent potential adverse effects must be based
on a clear determination of the importance to the public
health of the increment in information that can be obtained,
based on such factors as the number of patients likely to use
the drug after approval, the potential for use in high-risk
populations, and the biological plausibility of cardiovascular
risks.
There is general consensus on the nature of major cardio-
vascular risks. These comprise three broad categories: cardi-
ovascular death or major irreversible morbidity (e.g.
non-fatal MI and stroke); debilitating but reversible cardio-
vascular symptoms or events (e.g. ﬂuid retention sufﬁcient
to cause dyspnoea, palpitations, lightheadedness, syncope
due to non-lethal arrhythmias, angina, transient ischae-
mic attacks); and pathophysiological characteristics that
increase the likelihood of cardiovascular adverse events
Table 1 Sample sizes [as a function of power (type II error)] to
detect cardiovascular risk in a randomized, controlled clinical
trial, assuming risk in the placebo group is 0.33%/year, and each
participant is followed for 1 year (two groups, equal n/group,
type I error ¼ 0.05; two-tailed test)31
Ratio of event rate
(treatment
group:placeboa)
Power
80% 85% 90% 95%
1.1 995 500 1 138 800 1 332 700 1 648 100
1.2 260 700 298 100 349 000 431 600
2.0 13 500 15 500 18 100 22 364
3.0 2 600 5 300 6 200 7 700
Estimation of sample sizes based on normal approximation to binomial.
aEvent rates in the APC trial, 0.67%/year (drug) and 0.33%/year
(placebo), see text. Calculations per van Belle et al.31
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(e.g. hypertension, accelerated thrombogenesis, asympto-
matic arrhythmogenesis).22–24
Surrogate measures of risk
Cardiovascular events can be determined only by direct
clinical observation. However, potentially important patho-
physiological changes can be measured objectively to
predict events. The appropriateness of such pathophysiolo-
gical surrogates for determining cardiovascular beneﬁt is
controversial. At present, for example, the FDA accepts
only blood pressure reduction in hypertensive patients and
LDL reduction in hypercholesterolemic patients as surro-
gates for cardiovascular clinical beneﬁt. In assessing
adverse effects, however, greater latitude is accepted. For
example, both the FDA and the EMEA mandate measurement
of the electrocardiographic QT interval during drug develop-
ment, expecting that its substantial increase predicts poten-
tially lethal arrhythmia. The International Conference of
Harmonisation (ICH) documents E14 and S7B emphasize the
need for thorough assessments of the QT interval during pre-
clinical and clinical testing,25–27 supported by in vivo cardi-
ovascular safety studies and in vitro electrophysiological
studies, and generally to include a dedicated study speciﬁ-
cally to assess drug effect on cardiac repolarization.26,28
Inferences concerning adverse events from such data can
be overcome only with trials that measure clinical events
directly.
Nonetheless, surrogates are imperfect predictors of
adversity. For example, most drugs associated in humans
with the potentially lethal arrhythmia, torsades de pointes
(TdP), inhibit the rapidly activating delayed rectiﬁer potass-
ium current in myocardial tissues. In vivo or in vitro studies
that identify this activity may be useful for determining the
potential for drug-induced TdP; however, not all drugs that
cause QT prolongation act through the delayed rectiﬁer,
and not all will result in TdP.29 Also, clinically important
QT abnormalities may not be apparent pre-approval, even
though they may occur in some patients after marketing,
possibly due to unpredictable drug–drug interactions that
emerge only with multiple drug therapies that were
precluded in pre-approval trials.
Safety surrogates may indicate risk that may not be actu-
ated in all patients. Nonetheless, even an incompletely pre-
dictive surrogate may preclude approval if other therapies
can provide acceptable beneﬁt without the risk of
concern. On the other hand, even a moderate risk might
be acceptable if relatively greater beneﬁt is perceived,
though approval on this basis should lead to well-designed
post-marketing studies to evaluate mortality and major
morbidity. Thus, safety surrogates must be assessed case
by case, and structured post-approval monitoring is irre-
placeable for complete assessment of drug safety.
Timing of risk assessment
Detection of the potential for a cardiovascular safety
problem in pre-clinical or early clinical studies should lead
to detailed pre-approval deﬁnition of acceptable cardiovas-
cular safety if a drug is to be approved for non-
cardiovascular targets.
Pre-approval assessments of drug-associated risks com-
monly suffer from inadequate statistical power because of
the relatively modest pre-approval exposure requirements
imposed by regulatory agencies. Currently, post-approval
assessments usually suffer from inadequate controls, from
cohorts not representative of the population actually using
the drug, and from inadequate power to identify adverse
events. Brass et al.21 have proposed an approach to resol-
ving the latter problem by basing safety evaluations not on
point estimates but rather on the upper bounds of conﬁ-
dence intervals circumscribing the point estimate, allowing
predeﬁnition of the unacceptable risk level and accrual of
sufﬁcient events to provide power adequate to assess
whether risk is within the pre-determined acceptable
range. If the conﬁdence limit is acceptable relative to the
demonstrated beneﬁt of therapy, approval may be justiﬁed
to avoid delaying availability of effective therapy. The
approval letter and/or label could state the need for post-
marketing assessments for increasingly precise deﬁnition
of cardiovascular risk. Patient exposure needed to generate
the required events could be gathered by extending safety
follow-up beyond that required for the primary efﬁcacy end-
point in pre-approval trials, eliminating the need to design
and conduct new studies or to enrol additional patients in
pivotal trials.21
Acceptable mechanisms to evaluate
cardiovascular risk
Drug development should incorporate cardiovascular safety
assessment beginning with pre-clinical/animal studies of
drug effects on cardiac physiology/pharmacology. Phase 1
and 2 trials should evaluate pre-speciﬁed parameters includ-
ing, but not limited to, coagulation proﬁles, blood pressure,
blood lipid concentrations, left ventricular size and func-
tion, body weight, cardiac dimensions, QT intervals, and
other ECG parameters and, to the extent feasible, inter-
actions between drug effects and speciﬁc genomic or pro-
teomic characteristics. Data generated from these studies
provide the foundation upon which Phase 3 trials can be
designed.
Most Phase 3 trials of ‘non-cardiac’ drugs should pre-
specify measurement of cardiovascular events of interest,
clearly stating the diagnostic criteria by which these
events will be identiﬁed, and mandating regular measure-
ment of variables to detect clinically silent events. In
addition, the protocol should deﬁne a method for combining
the adverse experiences from all trials in the development
program to enhance power to identify problems if they
exist.
Given the relative frequency of the non-cardiac outcome
events in many of these trials, large sample sizes often are
not required for demonstrating superior beneﬁt of a new
agent vs. placebo if a beneﬁcial drug effect exists. Since
the need to avoid confounding inﬂuences in these relatively
small populations commonly results in relatively young
patients with low cardiovascular risk, the capacity to
detect cardiovascular adversity is inherently limited even
if such events truly are associated with therapy. For
example, when placebo-treated cohorts have annual event
rates for the pre-speciﬁed cardiovascular safety composite
as low as that found in the APC trial (earlier), population
sizes (and costs) for clinical trials would need to be several
orders of magnitude greater than typical pre-approval
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exposure for non-cardiac drugs (e.g. terfenadine ¼ 5000
patients, fenﬂuramine ¼ 340, dexfenﬂuramine ¼ 120030) if
trials were designed a priori to achieve power sufﬁcient to
establish clinically meaningful cardiovascular risk that is
1.5 to two-fold greater than placebo (Table 1). Enlarging
trials to identify statistically signiﬁcant differences in cardi-
ovascular risk between a new non-cardiovascular drug and a
comparator is rarely feasible and generally would represent a
wasteful expenditure of research resources. Non-inferiority
trial design also can be employed to assess relative safety;
regulators and investigators then would need to agree upon
the magnitude of difference between adverse event rates
caused by the new agent and those caused by an estab-
lished drug (or by placebo) that would be ‘clinically unimpor-
tant’. As in superiority trials, however, large numbers of
patients are needed when adverse events are relatively
uncommon (Table 2).
However, the absolute magnitude of risk reliably excluded
by trial data can be deﬁned from registries/observational
studies, less rigorous than randomized controlled trials for
comparisons of effects of different therapeutic strategies,
but perhaps better suited for providing credible absolute
risk estimates. Actual detection of relatively rare events is
likely to require a prohibitively large sample size (Table 3)
but excluding a risk of unacceptable magnitude can be
achieved with population sizes likely attainable in practice.
As projected in Table 4, such populations could provide
a point estimate of absolute risk, with narrower and
more credible conﬁdence intervals, than now is commonly
available, enabling more conﬁdent comparison of beneﬁt
and risk than currently is possible.
Observational studies are less intricate and costly and,
therefore, often more practical, than randomized trials for
deﬁning absolute risk. Also, compared with randomized
trials that must employ rigorous exclusion criteria to mini-
mize factors likely to confound data interpretation, observa-
tional studies of absolute risk do not necessarily require such
exclusions and, in fact, may avoid them to mimic the ‘real
world’ population at risk. Unfortunately, the strength of
the observational study also is its weakness: the lack of a
comparator and the potential for multiple confounders
limits the breadth of acceptable conclusions and can lead
to erroneous inferences, declaring a drug acceptably safe
when it is not, or unacceptably harmful when it is safe.
Sample sizes for observational studies depend on the pre-
deﬁned magnitude of acceptable risk and on decisions
about confounder exclusions.
To use observational studies for safety assessment, the
design must be prospective, with pre-speciﬁed deﬁnition
of cardiovascular outcomes. Retrospective assessment may
fail to provide documentation of variables of interest.
When comparative risks are required, randomized trials
may be the only acceptable design. The strength of evidence
inferrable from the study design must be considered when
evaluating drug safety.
Large insurance databases are often used in observational
studies to evaluate drug safety. These databases contain
thousands of patient records with up to several years of
Table 2 Number of patients needed to demonstrate non-inferiority assuming type I error ¼ 0.05 and power ¼ 0.90 (computation based on
Chow et al.32)
Non-inferiority margin Absolute risk for placebo
0.0033 0.02 0.05
Group nk sample size for n1 ¼ n2 Group nk sample size for n1 ¼ n2 Group nk sample size for n1 ¼ n2
30% 57 479 (total sample ¼ 114 958) 9 326 (total sample ¼ 18 652) 3 616 (total sample ¼ 7232)
50% 20 693 (total sample ¼ 41 386) 3 359 (total sample ¼ 6 718) 1 302 (total sample ¼ 2 604)
100% 5 174 (total sample ¼ 10 348) 840 (total sample ¼ 1 680) 326 (total sample ¼ 652)
Table 3 Minimum number of subjects to assure observing at least one event if the true event rate is 0.0001
Probability of observing at least 1 event when true event rate ¼ 0.0001
0.999 0.95 0.9 0.85 0.80
Number (n) of subjects needed in sample 46 050 29 956 23 025 18 971 16 094
Sample size computed from binomial distribution with p(x ¼ 1) ¼ 0.0001 and q(x ¼ 0) ¼ 0.9999 and solving for n.
Table 4 Sample size needed to determine if true event rate is 0.015 and not 0.02 (calculated from formula of van Belle et al.31)
One-tail type I error ¼ 0.01 One-tail type I error ¼ 0.025 One-tail type I error ¼ 0.05
Power 80% 90% 95% 80% 90% 95% 80% 90% 95%
Sample size 6420 8545 10529 5072 6978 8781 4039 5757 7404
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follow-up. Adequately powered studies using these data-
bases can be prospectively designed with strict procedures
for data collection and veriﬁcation. These databases can
be excellent tools for evaluating the long-term safety of car-
diovascular and non-cardiovascular drugs in much larger
populations than would be feasible in prospective random-
ized trials, though inferences from them are limited by
lack of information about doses actually used vs. those pre-
scribed, and by imprecision or inaccuracy in diagnoses and
other patient characteristics, since these generally are not
entered directly or checked by treating physicians.
Regulatory impediments to post-marketing
safety assessment
Currently, the FDA can request post-marketing studies, but
can legally require them only for new drugs approved under
Subpart H, granted on the basis of a surrogate endpoint or
when approval carries restrictions to ensure safe use. The
EMEA has parallel limitations. To improve post-marketing
safety assessment, all regulatory agencies must be empow-
ered to mandate adequately designed post-marketing
studies as a condition of approval, with the capacity to with-
draw approval if the sponsor does not perform the mandated
studies. Drug approval should be viewed as the initial, not the
ﬁnal, step in deﬁning appropriate drug use. The drug label
developed at the time of approval should be subject to con-
tinual reﬁnement in response to results of post-marketing
studies. Post-marketing experience should not be primarily
a basis for withdrawing marketing approval but rather a
basis for continually improving the precision of information
to prescribers/users about risks (and beneﬁts) to be con-
sidered in employing a therapy. In the early post-approval
period, a label could include a warning that ‘the cardiovascu-
lar risk has not been fully evaluated’ with a numerical state-
ment about the level of risk that cannot be excluded, to be
removed when risk is more fully examined. The label could
also indicate the date by which post-marketing evaluations
are anticipated.
Other considerations
Dose- response relations for safety end-points may differ
quantitatively from those for efﬁcacy. In addition, the
exposure time required to observe an adverse cardiovascu-
lar effect is not known; it is likely to be different for differ-
ent drugs. Drug-related risks may vary with the pre-therapy
cardiovascular risk of the patient. For example, a drug may
have minimal absolute cardiovascular risk in a young patient
without comorbid conditions, but it may be associated with
far greater absolute risk in a 70-year-old with known coron-
ary disease and diabetes. Thus, for non-cardiovascular
drugs, it may be useful to perform at least one efﬁcacy
study in patients with relatively high cardiovascular risk if
the drug will ultimately be used in this population; this
approach requires careful safety monitoring during the
trial. However, without empirical data, it cannot be known
if ﬁndings from a high-risk population (either positive or
negative) can be extrapolated to lower risk patients.
Finally, all risks may not be evident even if the processes
for assessing cardiovascular safety are revised.
Conclusion
Harms identiﬁed after drug approval during the past decade
suggest the need for new approaches to evaluating potential
cardiovascular risk in the context of non-cardiovascular
therapy. Unfortunately, currently feasible strategies
cannot guarantee detection and quantitation of all major
adverse drug effects; biological variability will continue to
provide uncertainty, which will be minimized only with phar-
macogenomic and other novel initiatives. Nonetheless, in
the present, we can and must improve upon efﬁciency in
deﬁning the risk:beneﬁt relations of non-cardiovascular
drugs. This will happen only if patient exposure, in number
and duration, is increased in pre- and post-approval
studies sufﬁciently to enable exclusion, with reasonable cer-
tainty, of unacceptable cardiovascular risks. Strategies to
achieve this goal, outlined in this article, may be useful.
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Lewis, PhD; Raymond Lipicky, MD; Alice Mascette, MD; M.A.P., MD,
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